TNFRSF9 and neoplasm: The broad range of 4-1BB expression on multiple cell types makes this receptor a dual-edged sword in the fight against cancer; as stimulation with 4-1BB agonists elicits strong anti-tumor responses from a myriad of cell types, however, sometimes at the cost of off-target immune pathology.